首页> 外文期刊>International Journal of Pharmaceutics >One-pot synthesis and characterization of ovalbumin-conjugated gold nanoparticles: A comparative study of adjuvanticity against the physical mixture of ovalbumin and gold nanoparticles
【24h】

One-pot synthesis and characterization of ovalbumin-conjugated gold nanoparticles: A comparative study of adjuvanticity against the physical mixture of ovalbumin and gold nanoparticles

机译:卵磷酸蛋白缀合金纳米粒子的单壶合成与表征:佐剂和金纳米粒子物理混合物的佐性对比研究

获取原文
获取原文并翻译 | 示例
           

摘要

Only few adjuvants are licensed for use in humans and there is a need to develop safe and improved vaccine adjuvants. In this study, we report the one-pot synthesis of antigen ovalbumin (OVA)-conjugated gold nanoparticles (OVA@GNPs). A systematical study was performed by comparing OVA@GNPs with the simple mixture of OVA and gold nanoparticles (OVA + GNPs), including their physiochemical properties through spectrometric and electrophoretic analysis, in vitro stability, cytotoxicity and cellular uptake, and in vivo humoral immune responses following subcutaneous and transcutaneous immunization in mice. The results demonstrate a much stronger interaction between protein and GNPs in OVA@GNPs than OVA + GNPs, which makes OVA@GNPs more stable under in vitro conditions than OVA + GNPs with the ability to induce 4 times higher OVA-specific serum IgG titers following subcutaneous immunization. We also show the dose sparing of OVA@GNPs, as the dosage for aluminum adjuvant required to reach to an equivalent OVA-specific antibody titer was almost five times higher than OVA@GNPs. However, we found that the co-administration of small-sized GNPs had a limited ability for the transcutaneous delivery of OVA. These results demonstrate the potential application of one-pot synthesis approach for producing antigen protein-conjugated gold nanoparticles for vaccine delivery.
机译:只有少数佐剂被许可用于人类,有必要开发安全和改善疫苗佐剂。在这项研究中,我们报告的一锅合成抗原卵清蛋白(OVA)缀合的金纳米粒子(OVA @国民生产总值)。一个系统化研究由@的GNP用OVA的金纳米颗粒(OVA +的GNP),包括通过光谱法和电泳分析它们的物理化学性质的简单混合物以及比较OVA,在体外稳定性,细胞毒性和细胞摄取进行,并且在体内体液免疫应答在小鼠皮下和经皮免疫。结果表明蛋白质和的GNP之间更强的相互作用在OVA @的GNP比OVA +的GNP,这使得OVA @的GNP更稳定的体外条件下比OVA +的GNP具有诱导以下4倍更高的OVA特异性血清IgG滴度的能力皮下免疫。我们还表明OVA的剂量节约@的GNP,作为用于铝佐剂剂量需要达到为等效的OVA特异性抗体滴度比OVA几乎高出五倍@的GNP。然而,我们发现,小尺寸的GNP联合政府不得不为OVA的经皮交付的能力有限。这些结果表明单釜合成方法的潜在应用用于产生抗原蛋白 - 缀合的金纳米粒子用于疫苗递送。

著录项

  • 来源
    《International Journal of Pharmaceutics》 |2019年第2019期|共10页
  • 作者单位

    Jiangsu Univ Sch Pharm 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Jiangsu Univ Sch Pharm 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Univ Copenhagen Fac Hlth &

    Med Sci Dept Pharm Univ Parken 2 DK-2100 Copenhagen O Denmark;

    Jiangsu Univ Inst Life Sci 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Jiangsu Univ Sch Pharm 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Jiangsu Univ Sch Pharm 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Univ Copenhagen Fac Hlth &

    Med Sci Dept Pharm Univ Parken 2 DK-2100 Copenhagen O Denmark;

    Jiangsu Univ Inst Life Sci 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

    Jiangsu Univ Sch Pharm 301 Xuefu Rd Zhenjiang 212013 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    Gold nanoparticles; Ovalbumin; One-pot synthesis; Subcutaneous; Transcutaneous; Immunization;

    机译:金纳米颗粒;卵磷酸酯;单盆合成;皮下;经皮;免疫;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号